Nairobi, Feb. 25 -- Kenya is among six African countries selected to participate in the World Health Organisation (WHO) and Medicines Patent Pool (MPP) mRNA Technology Transfer Programme, an initiative that aims to shift vaccine production from wealthy nations to countries that need them most.

The MPP is a United Nations-backed body that negotiates licensing agreements, allowing lower-income countries to access medical technologies, including vaccines, medicines, and diagnostics for diseases at affordable costs.

Through this technology transfer, the Kenya BioVax Institute will receive end-to-end training covering the full process from research and development through to large-scale production, while the Kenya Medical Research Institute ...